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Cerebrospinal fluid levels of inflammation,
oxidative stress and NAD+ are linked to differences
in plasma carotenoid concentrations
Jade Guest1,2, Ross Grant1,2,3*, Manohar Garg4, Trevor A Mori5, Kevin D Croft5 and Ayse Bilgin6
Abstract
Background: The consumption of foods rich in carotenoids that possess significant antioxidant and inflammatory
modulating properties has been linked to reduced risk of neuropathology. The objective of this study was to evaluate
the relationship between plasma carotenoid concentrations and plasma and cerebrospinal fluid (CSF) markers of
inflammation, oxidative stress and nicotinamide adenine dinucleotide (NAD+) in an essentially healthy human cohort.
Methods: Thirty-eight matched CSF and plasma samples were collected from consenting participants who required a
spinal tap for the administration of anaesthetic. Plasma concentrations of carotenoids and both plasma and cerebrospinal
fluid (CSF) levels of NAD(H) and markers of inflammation (IL-6, TNF-α) and oxidative stress (F2-isoprostanes, 8-OHdG and
total antioxidant capacity) were quantified.
Results: The average age of participants was 53 years (SD = 20, interquartile range = 38). Both α-carotene (P = 0.01) and
β-carotene (P < 0.001) correlated positively with plasma total antioxidant capacity. A positive correlation was observed
between α-carotene and CSF TNF-α levels (P = 0.02). β-cryptoxanthin (P = 0.04) and lycopene (P = 0.02) inversely correlated
with CSF and plasma IL-6 respectively. A positive correlation was also observed between lycopene and both plasma
(P < 0.001) and CSF (P < 0.01) [NAD(H)]. Surprisingly no statistically significant associations were found between the
most abundant carotenoids, lutein and zeaxanthin and either plasma or CSF markers of oxidative stress.
Conclusion: Together these findings suggest that consumption of carotenoids may modulate inflammation and
enhance antioxidant defences within both the central nervous system (CNS) and systemic circulation. Increased
levels of lycopene also appear to moderate decline in the essential pyridine nucleotide [NAD(H)] in both the
plasma and the CSF.
Keywords: Brain, Carotenoid, Inflammation, NAD+, Oxidative stress
Background
Neuroinflammation and oxidative stress have emerged
as key players in the complex interplay between environ-
mental and biological factors involved in the develop-
ment of neurodegenerative disease [1,2]. Under normal
homeostatic conditions both immune and oxidative
activity are largely transitory due to inherent negative
feedback mechanisms including increased production
of anti-inflammatory cytokines and enhanced endogenous
antioxidant (that is glutathione peroxidase, catalase or
superoxide dismutase) activity. During periods of chronic
disease however, these processes can be continuously
activated often amplifying each other in a positive feed
forward cycle, causing cell death, tissue dysfunction and
disease [3,4].
Neuroinflammation is a well-established feature of
the pathology associated with most neurodegenerative
disorders [5-7]. During various stages of disease the
activity of microglia and astrocytes are markedly increased
resulting in altered production of important signalling
molecules such as cytokines [8,9]. Secretion of the in-
flammatory cytokines TNF and IL-6 are reportedly up-
regulated within the central nervous system (CNS) of a
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number of neurodegenerative disorders including Alzhei-
mer’s disease (AD) [10]. While elevated levels of TNF
and IL-6 have been found to induce neuronal apoptosis
and tau protein phosphorylation respectively [11-14],
observations that IL-6 and TNF inhibit glutamate and
β-amyloid (Aβ) toxicity respectively also indicate potentially
neuroprotective roles [15,16]. At lower concentrations TNF
has also been shown to be involved in synaptic scaling,
cell signalling and a number of behavioural and auto-
nomic processes, leading some to consider this cytokine
as a neuromodulator [17-22]. Likewise, physiological levels
of IL-6 have been shown to possess neuromodulatory
properties, enhancing the differentiation of neurons and
expression and function of the neuronal adenosine A1
receptor, an important modulator of synaptic transmission
[23,24]. Evidence is thus emerging that cytokines such as
TNF and IL-6 can elicit either positive modulatory or
toxic effects in the CNS that is likely dependent on their
level of expression.
While the complex pathological and physiological roles
of inflammatory cytokines in the CNS are yet to be fully
understood, it is relatively well established that elevated
levels of each of these cytokines directly promote oxidative
stress [25-27]. The brain, and neurons in particular, are
especially vulnerable to oxidative stress as a consequence
of their poor antioxidant protection, high oxygen demand
and high levels of both polyunsaturated fatty acids and
transition metals [28]. The term ‘oxidative stress’, describes
a significant imbalance between antioxidant defences and
the bodies’ formation of reactive nitrogen (RNS) and/or
oxygen species (ROS) [29]. Accumulation of RNS/ROS
may result in a variety of detrimental effects such as pro-
tein oxidation, lipid peroxidation and DNA damage [2].
Failure to repair this damage, particularly to the DNA,
has been demonstrated to cause genomic instability and
neuronal apoptosis and is associated with the develop-
ment of several neuropathologies [2,30-32].
In order to maintain cellular integrity and homeostasis
after oxidative assault, a number of repair processes exist
including activation of the nicotinamide adenine dinucleo-
tide (NAD+) dependent DNA nick sensor poly(ADP-ribose)
polymerase-1 (PARP) [33]. Importantly PARP activation in
response to DNA damage catalyses the successive cleavage
of the ADP-ribose moiety from NAD+ resulting in the
formation of poly(ADP-ribose) subunits. In the context
of low-to-moderate DNA damage this process facilitates
DNA repair. However, over-activation of PARP, due to
excessive DNA damage, can result in neuronal death as
a consequence of decreased ATP production following
critical depletion of NAD+ [34]. In order to preserve
cellular energy and concomitantly PARP activity, adequate
levels of NAD+ must be maintained.
While age is the major risk factor for the development
of most neurodegenerative disorders [35,36], a number
of lifestyle choices have been linked to either promotion
or prevention of pathogenesis by increasing or decreasing
oxidative stress and inflammation. Carotenoids, a family
of phytochemicals synthesised by plants, that are respon-
sible for the red, orange, and yellow pigments of fruit and
vegetables, have been the subject of increased attention as
a result of their antioxidant and inflammatory modulating
properties. Importantly, serum carotenoids have been
shown to be positively associated with brain carotenoid
levels and can be considered a reliable predictor of brain
carotenoid concentrations [37].
Within the brain, carotenoids are thought to exert a
variety of protective effects. In a cell culture model of AD,
lycopene was shown to efficiently attenuate Aβ-induced
ROS formation, improve neuron viability and decrease
the rate of apoptosis [38]. Low serum levels of lycopene,
β-carotene, lutein and zeaxanthin have also been linked to
impaired cognitive function and AD [39-42]. Lutein sup-
plementation has also been shown to prevent erythrocyte
lipid peroxidation in humans and has been suggested as a
potential therapy for the prevention of dementia [43].
Collectively, these reports indicate that higher caroten-
oid levels may mitigate against the development of an
oxidative-inflammatory state and thereby reduce tissue
damage within the CNS. While evidence from cell culture,
animal and limited post-mortem brain tissue studies
support this hypothesis, to date no study has investigated
this putative association in the CNS of a healthy human
cohort. Therefore the objective of this study was to evalu-
ate the relationship between plasma concentrations of
carotenoids and plasma and cerebrospinal fluid (CSF)
markers of inflammation, oxidative stress and NAD+ in
an essentially healthy human cohort.
Methods
Ethics statement
This study was conducted in accordance with the Helsinki
declaration. Ethical approval was obtained from the
Human Research Ethics Committee, Sydney Adventist
Hospital (EC00141, project number 2011-005). Written
informed consent was obtained from all participants
prior to commencement.
Participants
Male (n = 10) and female (n = 28) participants, who re-
quired a spinal tap for the administration of anaesthetic
as part of routine care (that is prior to surgery), were
recruited at Sydney Adventist Hospital, Australia as part of
a larger health study [44]. The average age of participants
was 53 years (SD = 20, interquartile range = 38). Partici-
pants were excluded from the cohort if they were smokers
or had a confirmed diagnosis of a neurological/neurodegen-
erative disorder or CNS infection. In total thirty-eight CSF
Guest et al. Journal of Neuroinflammation 2014, 11:117 Page 2 of 10
http://www.jneuroinflammation.com/content/11/1/117
and matched blood samples were collected from consent-
ing participants considered in general good health.
Sample collection
CSF and blood samples (fasting ≥ ten hours) were collected
by an anaesthetist no longer than 30 minutes apart. Blood
was collected into heparinised tubes from a superficial vein
on an upper limb, prior to the administration of fluids
or anaesthetics. CSF samples were collected via standard
lumber puncture prior to injection of anaesthetics. Sam-
ples were centrifuged for 10 minutes at 1,800 rpm and
stored at −194°C within 1 hour of collection, for a max-
imum of 12 months, until analysis. Samples intended for
F2-isoprostane analysis where stored in the presence of a
glutathione/butylated hydroxytoluene preservative.
Biochemical analysis
Total nicotinamide adenine dinucleotide (NAD(H)) con-
centrations were measured spectrophotometrically using
a thiazolyl blue microcycling assay established by Bernofsky
and Swan [45], and adapted to a 96-well plate format by
Grant and Kapoor as previously described [46,47].
IL-6, TNF-α, total antioxidant capacity (TAC) and 8-
hydroxy-2′-deoxyguanosine (8-OHdG) were measured
using a standardised commercial solid phase sandwich
enzyme-linked immunosorbent assay (ELISA) (Human
IL6 High Sensitivity ELISA Kit, Abcam, Cambridge,
MA, USA; Human TNF-α UltraSensitive, Invitrogen
Corporation, Camarillo, CA, USA; Antioxidant Assay Kit,
Cayman Chemical Company, Ann Arbor, MI, USA; Highly
Sensitive 8-OHdG Check, Japan Institute for the Control of
Ageing, Shizuoka Japan).
Total F2-isoprostanes were measured by gas chromatog-
raphy-mass spectrometry (GC-MS) using electron capture
negative ionisation according to a modification in the
method of Mori et al. as previously described [48,49].
Plasma carotenoids were measured using high-perform-
ance liquid chromatography according to the method
established by Barua and colleagues and previously de-
scribed (Figure 1) [50,51].
Statistical analysis
Statistical analyses were performed using SPSS version
16.0 for Windows (SPSS Inc., Chicago, IL, USA). Data
is presented as means ± standard deviation (SD) unless
otherwise stated. The Pearson correlation coefficient and
multiple linear regression, controlling for age and gender,
was used to identify significant relationships between
carotenoids, [NAD(H)], and markers of oxidative stress
and inflammation. Normality was assessed using histo-
gram, Shapiro-Wilk and Kolmogorov-Smirnov analysis.
Because some carotenoids (lutein and zeaxanthin, β-
cryptoxanthin, lycopene, total carotenoids) and both
plasma and CSF IL-6 showed slightly skewed distributions,
analyses were performed using base-10 log-transformed
data. Adjusted and non-adjusted P-values are provided
throughout with test significance set at P-value ≤ 0.05.
Results
The mean plasma concentrations of individual carotenoid
pigments are presented in Table 1.
Association between carotenoids and inflammatory
cytokines
A significant inverse association was observed between
plasma levels of lycopene and plasma IL-6 (P < 0.001,
r = −0.53, n = 34) (Figure 2A). This association remained
even after controlling for age and gender (P = 0.02,
R2 = 0.21). An increase in lycopene of 1% was associated,
on average, with a 0.54% decrease in plasma IL-6. Higher
plasma total carotenoid concentrations were also associ-
ated with lower levels of plasma IL-6 (P = 0.01, r = −0.44,
n = 34) (Figure 2B), however this relationship did not
remain statistically significant after controlling for age and
gender (P = 0.06). No associations were found between
plasma IL-6 and any other individual carotenoid.
An increase in plasma β-cryptoxanthin levels was as-
sociated with a decrease in CSF IL-6 (P = 0.04, r = −0.34,
n = 36) (Figure 2C). This association remained even after
controlling for age and gender (P = 0.04, R2 = 0.45). An
increase in β-cryptoxanthin by 1% was associated, on
average, with a 0.33% decrease in CSF IL-6. Higher plasma
total carotenoids were also associated with reduced
levels of CSF IL-6 (P = 0.01, r = −0.44, n = 36) however
this relationship did not remain statistically significant
after controlling for age and gender (P = 0.06) (Figure 2D).
A trend between increased plasma lycopene levels and
reduced concentrations of CSF IL-6 was observed, how-
ever this was not statistically significant (P = 0.22). No
associations were found between CSF IL-6 and any other
individual carotenoid.
An increase in plasma α-carotene was associated with
an increase in CSF TNF-α (P = 0.01, r = 0.185, n = 36)
(Figure 3). This association remained even after controlling
for age and gender (P = 0.02, R2 = 0.10). A ten-fold increase
in α-carotene was associated with a small 0.003 pg/mL in-
crease in CSF TNF-α. A positive trend between β-carotene
and CSF TNF-α was also observed, however this did not
reach statistical significance (P = 0.17). No associations
were found between CSF TNF-α and any other individual
carotenoid.
Association between carotenoids and markers of
oxidative stress
A significant positive association was observed between
both α-carotene (P = 0.01, r = 0.43, n = 33) and β-carotene
(P < 0.001, r = 0.59, n = 33) and the total antioxidant
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capacity (TAC) in plasma (Figure 4). These relation-
ships remained even after controlling for age and gender
(P = 0.01, R2 = 0.14; P < 0.001, R2 = 0.32 respectively). A
1 ng/mL increase in α-carotene or β-carotene was associ-
ated with a 0.15 or 0.04 nmol/mg protein increase in
plasma TAC respectively. When controlling for age and
gender, higher plasma levels of lycopene also tended to
correspond with reduced levels of plasma F2-isoprostanes,
however this did not quite reach statistical significance
(P = 0.06). An apparent inverse trend between CSF F2-
isoprostane levels and plasma β-cryptoxanthin (P = 0.16),
α-carotene (P = 0.14) and β-carotene (P = 0.20) was ob-
served, though these did not reach statistical signifi-
cance. No further associations were apparent between
CSF F2-isoprostane and plasma levels of any individual
carotenoid. No associations were observed between
CSF 8-OHdG concentrations and plasma levels of any
individual carotenoid.
Association between carotenoids and both peripheral and
central [NAD(H)]
A significant positive association was found between lyco-
pene and both plasma (P < 0.01, r = 0.50, n = 38) and CSF
(P < 0.01, r = 0.50, n = 37) [NAD(H)] (Figure 5). These
relationships remained even after controlling for age and
gender (P < 0.001, R2 = 0.31; P < 0.001, R2 = 0.21 respect-
ively). A 1% increase in lycopene was associated, on average,
with a 0.20% increase in plasma [NAD(H)]. Likewise a ten-
fold increase in lycopene was associated with a 48.4 μg/mL
increase in CSF [NAD(H)].
After controlling for age and gender a positive association
between total carotenoids and plasma NAD(H) levels was
also observed (P = 0.03, R2 = 0.12, n = 37) (Figure 5C). A 1%
increase in total carotenoids was associated, on average,
with a 0.21% increase in plasma [NAD(H)]. Plasma
total carotenoids were positively associated with CSF
[NAD(H)] (P = 0.05, r = 0.33, n = 37), however this did not
remain statistically significant after controlling for age and
gender. No associations were found between plasma [NAD
(H)], CSF [NAD(H)] and any other individual carotenoid.
Discussion
Neuroinflammation and oxidative stress are established
pathological features of most neurodegenerative disorders.
While the consumption of foods rich in carotenoids, known
to possess antioxidant and inflammatory modulating prop-
erties, has been linked to a reduced risk of cognitive decline
Figure 1 An example chromatograph of plasma carotenoids as measured by HPLC.
Table 1 Mean plasma carotenoid concentrations
Carotenoid Mean (ng/mL) ± SD
Lutein and zeaxanthin 538.24 ± 338.15
β-cryptoxanthin 59.54 ± 54.91
Lycopene 218.86 ± 176.80
α-carotene 15.19 ± 14.92
β-carotene 80.46 ± 82.13
Total carotenoids 935.02 ± 474.95
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[40], surprisingly there is limited research on the effect of
carotenoids on neuroinflammation and oxidative stress. To
our knowledge this is the first study to investigate the asso-
ciation between peripheral carotenoid concentrations and
CNS markers of oxidative stress and inflammation in
humans without CNS pathology.
As expected, high plasma lycopene and total carotenoid
concentrations were associated with reduced plasma
IL-6 levels. This is consistent with epidemiologic studies
reporting carotenoid concentrations to be inversely
associated with peripheral markers of inflammation [52].
While further research into the mechanism of carotenoid
mediated inflammation is required, it has been demon-
strated that a variety of carotenoids, including lycopene
and lutein inhibit cytokine production via suppressing
ROS stimulated NF-κβ activation [53-56].
While major contributors to plasma TAC are uric acid
and albumin [57], the positive correlation observed between
plasma TAC and both α-carotene and β-carotene indicate
that these carotenoids contribute to peripheral antioxidant
defences. However, their capacity to mitigate against both
lipid and DNA damage in vivo is questionable as no inverse
associations were observed between carotenes and either
plasma F2-isoprostane or 8-OHdG respectively. Previous
evidence for an association between the carotenes and
markers of lipid and DNA oxidative damage is mixed,
with some studies showing a significant protective effect
and others finding no significant association [58-61]. For
example van den Berg and colleagues reported that
while a three-week plant-based diet increased serum
levels of carotenoids, including α-carotene and β-
carotene, and increased TAC, consistent with results
from this study, no effects were observed on any
plasma marker of oxidative damage to lipids, proteins
and DNA [61].
A number of carotenoids, including β-cryptoxanthin,
lycopene and β-carotene, are thought to cross the blood
brain barrier and modulate inflammation [62,37]. In this
Figure 2 Association between carotenoids and reduced levels of peripheral and central IL-6. (A) Inverse association between plasma
lycopene and plasma IL-6 levels. A significant inverse association exists between plasma lycopene and plasma IL-6 (P = 0.02, R2 = 0.21, n = 34).
Comparisons were made using multiple linear regression controlling for age and gender. (B) Inverse association between plasma total carotenoids
and plasma IL-6 levels. A significant inverse association exists between total plasma carotenoids and plasma IL-6 (P = 0.01, r = −0.44, n = 34), however
this relationship does not remain statistically significant after controlling for age and gender (P = 0.06). Comparisons were made using the Pearson
correlation coefficient and multiple linear regression controlling for age and gender. (C) Inverse association between plasma β-cryptoxanthin
and cerebrospinal fluid (CSF) IL-6 levels. A significant inverse association exists between plasma β-cryptoxanthin and CSF levels of IL-6 (P = 0.04,
R2 = 0.45, n = 36). Comparisons were made using multiple linear regression controlling for age and gender. (D) Inverse association between
total carotenoids and CSF IL-6 levels. A significant inverse association exists between plasma total carotenoids and CSF levels of IL-6 (P = 0.01,
r = −0.44, n = 36), however this relationship does not remain statistically significant after controlling for age and gender (P = 0.06). Comparisons
were made using the Pearson correlation coefficient and multiple linear regression controlling for age and gender.
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study a novel inverse association between β-cryptoxanthin
and CSF IL-6 was observed. Similarly an increase in total
carotenoids was also associated with reduced CSF IL-6
levels. This is consistent with in vitro work by others
showing that β-cryptoxanthin significantly attenuates both
the release and transcription of various cytokines [63,64].
Astaxanthin, another member of the carotenoid xantho-
phyll family, has also been shown to decrease IL-6 mRNA
in activated microglia [65].
In contrast to the inverse associations observed between
carotenoids and IL-6, an increase in plasma α-carotene
was associated with a statistically significant increase in
CSF TNF-α. A positive, though not statistically significant
trend was also observed between β-carotene and CSF
TNF-α. While evidence of the moderating effect of carot-
enoids on inflammation is growing, consistent with results
from this study, a small number of in vitro and ex vivo
studies have reported that β-carotene can increase the
secretion of TNF-α from monocytes and macrophages
[66,67]. Although no known studies have investigated the
potential for α-carotene to likewise promote TNF-α secre-
tion, the structural similarity between both carotene
types suggest this possibility and is consistent with the
data presented in this manuscript, though further research
is required to verify this observation.
TNF-α is a multifunctional, pleiotropic cytokine initially
identified as a potent regulator of cellular activity during
an immune response. Although traditionally considered
toxic and known to initiate neuronal apoptosis when ele-
vated [13] in healthy brain tissue under non-inflammatory
conditions, physiological TNF-α levels below approximately
20 (pg/mL) appear to have positive neuromodulatory
activity [17,68-72]; being involved in synaptic scaling,
cell signalling and a number of behavioural and autonomic
processes [17-21]. Under certain circumstances TNF-α
has also displayed neuroprotective properties such as
preventing Aβ toxicity [15]. While the role of TNF-α
in normal brain function is yet to be fully elucidated,
considered together, these studies indicate that phy-
siological levels of TNF-α, as observed in this study
(2.69 pg/mL ± 0.68 SD) may play a role in maintaining
neural homeostasis. Therefore, our finding of a posi-
tive association between the carotenes and TNF-α levels
(within the lower physiological range) likely do not reflect
increased inflammation, but rather promotion of the
healthy neuromodulatory function of TNF-α.
There is a growing interest in understanding the role
and mechanism of the carotenoids as inhibitors of oxi-
dative stress. Indeed evidence suggests that the ability of
Figure 4 Positive association between plasma total antioxidant
capacity (TAC) and (A) plasma α-carotene (B) plasma β-carotene.
(A) A significant positive association exists between plasma α-carotene
and plasma TAC (P = 0.01, R2 = 0.14, n = 33). Comparisons were made
using multiple linear regression controlling for age and gender. (B) A
significant positive association exists between plasma β-carotene and
plasma TAC (P < 0.001, R2 = 0.32, n = 33). Comparisons were made
using multiple linear regression controlling for age and gender.
Figure 3 Positive association between cerebrospinal fluid (CSF)
TNF-α and plasma α-carotene. A significant positive association
exists between plasma α-carotene and CSF TNF-α (P = 0.02, R2 = 0.10,
n = 36). Comparisons were made using multiple linear regression
controlling for age and gender.
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carotenoids to combat oxidative stress does not solely
rely on their capacity to quench free radicals. Recently
lycopene, a potent singlet oxygen (1O2) quencher [73], has
been reported to restore PARP activity after deltamethrin-
induced testicular injury in rats [74]. Further Apo-10′
lycopenoic acid, a lycopene metabolite, has been shown in
murine models to increase sirtuin 1 (SIRT1) mRNA and
protein levels [75]. Importantly, both PARP and SIRT1
use NAD+ as the primary substrate for their activities. We
report for the first time a significant positive association
between lycopene and both plasma and CSF NAD(H)
levels, which remained even after controlling for age and
gender. While further investigation is required, we postu-
late that by quenching ROS, lycopene reduces DNA
damage, preventing PARP over-activation, and hence
preservation of central NAD+ stores.
NAD+ is a ubiquitous molecule that is necessary for a
number of vital cellular processes. In addition to its role
in classical energy production and many cellular reactions
as a redox couple, NAD+ also serves, as previously men-
tioned, as a substrate for the sirtuin and PARP family of
enzymes and the immune linked NAD+ glycohydrolases
(CD38) [76-78]. As a group, these NAD+ dependent en-
zymes help modulate circadian rhythms, insulin secretion,
genomic stability and cell longevity [79-83]. As NAD(H)
levels impact at least PARP and SIRT1 activity, our obser-
vation that lycopene correlates with increased NAD(H)
availability within the brain suggests that consumption of
this carotenoid may improve cell metabolic and genomic
stability, decreasing an individuals’ susceptibility to neuro-
degenerative disease. This is of potential significant rele-
vance in light of observations by others that higher
levels of NAD+ correlate with reduced synaptic loss and
increased neuronal viability [84,85], and the need to find
effective strategies to maintain cell function in the aging
brain.
While the observations reported in this study are statisti-
cally valid, it is recognised that these associations have been
obtained from a modest number of matched whole blood
and CSF samples, potentially limiting sensitivity. As a result,
some relationships may have been obscured; for example,
although no statistically significant association between
Figure 5 Association between carotenoids and increased levels of
peripheral and central [NAD(H)]. (A) A significant positive association
exists between lycopene and plasma [NAD(H)] (P < 0.001, R2 = 0.31,
n = 38). Comparisons were made using multiple linear regression
controlling for age and gender. (B) A significant positive association
exists between lycopene and CSF [NAD(H)] (P < 0.001, R2 = 0.21,
n = 37). Comparisons were made using multiple linear regression
controlling for age and gender. (C) A significant positive association
exists between total carotenoids and plasma [NAD(H)] (P = 0.03,
R2 = 0.12, n = 37). Comparisons were made using multiple linear
regression controlling for age and gender.
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carotenoids and specific biomarkers of lipid and DNA
damage was found, a number of expected inverse trends
were observed that may have reached statistical signifi-
cance if sample numbers were increased. In addition,
some observed associations did not remain significant
after controlling for age and gender (for example, between
CSF IL-6 and serum total carotenoids) which may yet
prove significant in a larger cohort study. In the case of
age, this may also reflect the relative inability of caroten-
oids to exert enough anti-inflammatory effect on their
own to combat the known age associated acceleration in
inflammation and oxidative stress [47,86]. Nevertheless
the reported associations in this study are generally con-
sistent with the limited number of previously published
observations and represent the first data linking carotenoid
levels with changes in [NAD(H)] and inflammatory/oxida-
tive stress markers in the healthy CNS.
Conclusion
An extensive body of evidence now indicates that oxida-
tive stress and inflammation play a central role in the
development of neurodegenerative disorders. While the
consumption of foods rich in carotenoids have been
linked to a reduced risk of this type of neuropathology,
limited research is available detailing their association
with inflammation and oxidative stress levels within the
human CNS. This study provides evidence for the first
time that plasma carotenoids may modulate CSF levels
of inflammatory cytokines in healthy humans and reports
a link between increased plasma carotenoid concentra-
tions and reduced oxidative activity. We also provide
novel evidence that lycopene may influence levels of the
essential pyridine nucleotide NAD(H) in both the plasma
and the CSF. This data therefore suggests that higher
carotenoid intake may assist in the maintenance of brain
health, however further research (both cross-sectional and
longitudinal) is required to confirm this proposition.
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